Skip to content
left end
left end
right end

Clinical trials open at BHOC

Availability of the studies below are subject to ongoing review, and according to constraints as a result of the COVID-19 pandemic.

 

IMPACT COVID IN BMT

ON/2020/6981

A prospective non interventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 infection

COVID-19

TACTIC-R

ON/2020/6990

Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)

COVID-19

RECOVERY

ON/2020/6969

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

COVID-19

 

ALL RICON/2018/6521

A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.

BMT

AMADEUSON/2019/6730

A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation

BMT

AUTOLUS

ON/2019/6890

AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

BMT

COSION/2019/6739

An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation

BMT

GRAVITAS

ON/2019/6731

A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

BMT

 

PARADIGM

ON/2015/4787

PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.

Brain

PARADIGM-2

ON/2017/6257

OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newlydiagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies

Brain

 

 

 

AURORA

ON/2015/4783

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer

Breast

KEYNOTE 756

ON/2018/6570

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast Cancer (KEYNOTE-756)

Breast

OPTIMA

ON/2012/4082

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

Breast

PARTNER

ON/2016/6055

 

Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA

Breast

 

 

TRIGGER

ON/2016/6035

TRIGGER - Magnetic Resonance Tumour Regression Grade (mrTRG) As A Novel Biomarker To Stratify The Management Of Good And Poor Responders To Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial

Colorectal

NSCCG

ON/2004/1707

NSCCG - National Study of Colorectal Cancer Genetics

Colorectal

TRACC

ON/2019/6877

TRACC - Tracking mutations in cell free tumour DNA to predict Relapse in Early Colorectal Cancer

Colorectal

PLATO

ON/2016/6076

PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5

Colorectal

 

NETTER 2

ON/2019/6876

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET.

Gastroenteropancreatic neuroendocrine

 

 

 

 

UK3PBEP

ON/2017/6193

UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Germ cell

 

 

 

 

COPELIA

ON/2018/6659

A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.

Gynaecology

RANGO

ON/2019/6913

Rare Neoplasms of Gynaecological Origin

Gynaecology

EMBRACE II

ON/2018/6697

Image guided intensity modulated external beam radiochemotherapy and MRI based adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-II)

Gynaecology

IOVANCE

LN-145

ON/2017/6447

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Gynaecology

 

 

 

AML LI-1

ON/2011/3722

Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial

Leukaemia 

AML 18

ON/2013/4465

A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Leukaemia

AML 19

ON/2015/4795

Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Leukaemia

AML PATIENT PATHWAY

ON/2019/6844

AML Qualitative Interview Study: Characterizing the patient journey - Adults with acute myeloid leukemia (AML) who are unsuitable for intensive chemotherapy

Leukaemia

CALLS

ON/2018/6544

A Cohort Study To Establish the Prevalence of Mutations in Patients with CML Who Meet the ELN Criteria for Warning or Failure and Patients With Ph+ALL With Detectable BCR-ABL1 Currently Being Treated With First or Subsequent TKI Therapy in the UK Using Next Generation Sequencing

Leukaemia

FLAIR

ON/2014/4605

FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab

Leukaemia

INO

ON/2019/6864

A retrospective chart review of UK patients with relapsed/refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin, a real world research study

Leukaemia

CYTARABINE SENSITIVITY

ON/2009/3221

Bacterial Biosensors for rapid pre screening of chemotherapy efficacy. (Cytarabine sensitivity study).

Leukaemia

UKALL 14

ON/2010/3418

A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

Leukaemia

VIALE-M

ON/2020/6924

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Leukaemia

TREATT

ON/2015/4769

A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe thrombocytopenia

Haematology (non- malignant)

 

 

 

 

 

 

 

 

 

 

COMPARE

ON/2015/4801

Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Head & Neck

INATT

ON/2017/6252

interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project

Head & Neck

BEST OF

ON/2018/6507

Phase III study assessing the "Best-Of" radiotherapy compared to the "Best-Of" surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma

Head & Neck

PATHOS

ON/2014/4740

A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

 

Head & Neck

TORPEDO

ON/2020/6887

A phase III trial of intensity-modulated proton beam therapy versus intensity modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

Head & Neck

COSMIC 311

ON/2019/6742

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Head & Neck

 

 

 

 

 

 

 

 

CANAKINUMAB CANOPY-A

ON/2018/6498

A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)

Lung

MATRIX

ON/2016/5052

National Lung Matrix Trial: Multi-­drug, genetic marker-directed, non­-comparative, multi-­centre, multi­-arm phase II trial in non-small cell lung cancer

Lung

HALT

ON/2019/6856

Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours

Lung

KEYNOTE 867

ON/2019/6750

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Lung

SMP2

ON/2018/6474

The Cancer Research UK Stratified Medicine Programme: Pilot Study

Lung

SARON

ON/2016/5099

Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial.

Lung

ADSCAN

ON/2017/6322

A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer.

Lung

 

 

C2-EuroNet

CH/2017/6449

Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents

Lymphoma

LYMRIT 37-01

ON/2014/4761

A phase I/II study of 177Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma

Lymphoma

LYMRIT 37-07

ON/2018/6698

A phase 1b open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma (Archer-1)

Lymphoma

LYMRIT 37-05

ON/2016/6020

A Phase 1 Dose finding study of 177Lu-DOTA-HH1 (Betalutin®) in patients with relapsed, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant

Lymphoma

 

 

 

ROAM

ON/2016/6029

Roam

Meningioma

 

 

FITNESS

ON/2019/6853

frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).

Myeloma

MYELOMA XII

ON/2016/6119

A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma.

Myeloma

 

 

 

 

ADD ASPIRIN

ON/2014/4750

A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

Non specific

ICI GENETICS

ON/2019/6726

Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity

Non specific

QOL

ON/2018/6537

Accounting for the impact of fluctuating health states on quality of life measures included in economic evaluation

Non specific

RAGNAR

ON/2019/6830

A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations

Non specific

IOV-COM-202

ON/2018/6703

A Phase 2, Open-label, 3-Cohort, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes LN 144/LN-145 as a Single-Therapy, or in Combination with Pembrolizumab, to Treat Solid Tumors in Patients with Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma, and Non-Small-Cell Lung Cancer

Non specific

RAPPER

ON/2006/2411

Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy

Non specific

 

                                       

 

REECUR

CH/2014/4655

International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

Sarcoma

EURO-EWINGS PK STUDY

CH/2013/4475

Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing's sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation (PK 2013 01)

Sarcoma

 

C-POST

(REGENERON)

ON/2019/6792

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE- BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CSCC

Skin

 

 

 

 

 

GLOW

ON/2018/6701

A Phase 3, Global, Multi-Centre, Double-Blind, Randomised, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Upper GI

KEYNOTE 585

ON/2018/6633

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)

Upper GI

PLATFORM

ON/2015/4788

Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial)

Upper GI

ABC-07

ON/2019/6821

Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers

Upper GI

PRECISION PANC

ON/2018/6484

PRECISION-Panc: Advancing personalised medicine treatment strategies for pancreatic cancer.

Upper GI

PRIMUS 001

ON/2018/6472

PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

Upper GI

SCOPE 2

ON/2015/4947

A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)

Upper GI

TACE-3

ON/2019/6707

A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC

Upper GI

 

 

 

ACE

ON/2017/6331

A study to evaluate cognitive function in metastatic castrate resistant prostate cancer (mCRPC) patients treated with Abiraterone Acetate (AA) or Enzalutamide (ENZ).

Urology

ATLANTIS

ON/2016/6186

An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer

Urology

ENZA-D

ON/2020/7028

A PILOT STUDY TO INVESTIGATE THE EFFECT OF ENZALUTAMIDE ON THE ANTI-XA LEVELS OF PATIENTS RECEIVING DIRECT-ACTING ANTICOAGULANTS (DOACS)

Urology

KEYLYNK 010

ON/2019/6719

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next generation Hormonal Agent (NHA) and Chemotherapy

Urology

KEYNOTE 641

ON/2019/6721

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Urology

KEYNOTE 921

ON/2019/6718

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

Urology

THOR

ON/2018/6514

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Urology

UKGPC

SU/2003/1415

UK Genetic Prostate Cancer Study

Urology

PACE-CON/2019/6908

PACE: International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy vs SBRT for organ-confined prostate cancer

 

Urology

PIVOTALBOOST

ON/2017/6393

A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost

Urology

RAMPART

ON/2018/6600

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Urology